Imclone has a load of cash. Erbitux stands by itself as the EGFr of choice for its activity in colon cancer, head and neck cancer and lung cancer. It has cash, manufacturing facilities, a pipeline paid for by Bristol Myers, and few expenses. Returns on capital once the erbitux gusher begins to flow will be large

Owns one of the newest franchises in devices. As with most new things, a rocky start to the use of VNS device in depression. But the margins are high, manufacturing cost low and market is huge.

Company has cash and two oncology drugs with confirmed activity.

A merger with XM, if it were to occur would increase the profitability of the company by a very significant amount and make it very valuable entity in radio.

While the short story gets the headlines, the real story is operating margins. Margins go up disproportionately after the fixed cost of running Overstock.com's tech platform are paid for. More revenue largely comes with no cost attached.

Sub prime mortgage guarantor that if it survives will be the beneficiary of the survival effect of dominating a devastated industry.

Monopoly on phone portage in land and cell lines.

Apple gets a piece of every subscriber dollar that comes through its iPhone partners. That's 100% margin revenue. Each iPhone user, like each iPod user is that much more willing consider purchasing one of Apple's i brand products.